Normoblastemia in COVID-19 patients is associated with more severe disease and adverse outcome.

Kenneth Ofori, Diane Chen, Jorge Sepulveda, Govind Bhagat, Bachir Alobeid

Abstract read

In one paragraph

Article in International journal of clinical and experimental pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kenneth OforiDepartment of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center New York, NY, USA.

Diane ChenDepartment of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center New York, NY, USA.

Jorge SepulvedaDepartment of Pathology, George Washington University Washington, DC, USA.

Govind BhagatDepartment of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center New York, NY, USA.

Bachir AlobeidDepartment of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe clinical, pathological, and laboratory correlates of normoblastemia in COVID-19 patients have not been adequately explored. We sought to assess the frequency of normoblastemia in COVID-19, its association with other markers of disease, as well as other clinical outcomes.

methodsAll COVID-19 patients seen at our institution with at least one automated complete blood count (aCBC) evaluation from March to May 2020 were included in this retrospective cohort analysis. Results of aCBC and tests for markers of the acute phase response performed within 5 days before the first COVID-19 positive test and 14 days after the last positive test were reviewed. We also evaluated histologic features of the reticuloendothelial system of COVID-19 decedents.

resultsAmong a total of 2501 COVID-19 patients, 715 (28.6%) were found to have normoblastemia. Patients with this abnormality had significantly higher (median, (1

conclusionNormoblastemia in COVID-19 is associated with markers of severe disease, extramedullary erythropoiesis, and adverse clinical outcome.

Indexed as

acute phase responseCOVID-19extramedullary erythropoiesisleukoerythroblastosisnormoblastemia

Identifiers

PMID37818385

PMCPMC10560885

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.